Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents

APLAR Journal of Rheumatology

Volumn 9, Issue 2, 2006, Pages 184-192

  Lichauco, Juan Javier T ^a,b   Tankeh Torres, Sandra A ^a   Navarra, Sandra V ^a   Dans, Leonila F ^a  

^a Philippine College of Chest Physicians (PCCP TB Council)   (Philippines)

^b ST LUKE S MEDICAL CENTER   (Philippines)

Author keywords

Biologic agents; Philippine guidelines; TNF blocking agents; Tuberculosis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGIC AGENT; CORTICOSTEROID; ETANERCEPT; ETHAMBUTOL PLUS ISONIAZID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ISONIAZID; PREDNISONE; PYRAZINAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC ACCURACY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; EXTRAPULMONARY TUBERCULOSIS; FEVER; HEMOPTYSIS; HOUSEHOLD; HUMAN; IMMUNE DEFICIENCY; INFECTION CONTROL; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG TUBERCULOSIS; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NONHUMAN; OPPORTUNISTIC INFECTION; PHILIPPINES; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT PLANNING; TUBERCULIN TEST; WEIGHT REDUCTION;

EID: 33745968907     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00182.x     Document Type: Article

References (28)

1. Goronzy JJ, Weyand CM (2001) Rheumatoid arthritis: Epidemiology, pathology, and pathogenesis. In: Klippel JH (Ed.) Primer on the Rheumatic Diseases, pp 209-17. Arthritis Foundation, Atlanta.
2. Arend SM, Breedveld FC, van Dissel JT (2003) TNF-α blockade and tuberculosis: Better look before you leap. Neth J Med 61, 111-8.
3. Gardam MA, Keystone EC, Menzies R, et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet 3, 148-55.
4. Furst DE, Breedveld FC, Kalden JR, et al. (2004) Updated consensus statement on biological agents, specifically tumour necrosis factor (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1 ra), for the treatment of rheumatic diseases. Ann Rheum Dis 63 (Suppl II), ii2-12.
5. Gomez-Reino JJ, Carmona L, Valverde VR, et al. (2003) on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 48, 2122-7.
6. Keane J, Gershoon S, Wise RP, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345, 1098-104.
7. Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmune Rev 4, 162-70.
8. Fleischmann R, Stern R, Iqbal I (2004) Anakinra: An inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 4, 1333-44.
9. Fleischmann RM (2002) Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-met HulL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF alpha agents. Clin Exp Rheumatoloct 20, S35-41.
10. Rose DN (2000) Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 160, 1513-21.
11. Task Force on Philippine Guidelines on Periodic Health Examination (2004) Screening for Active Tuberculosis (TB) Disease and Latent Tuberculosis Infection (LTBI). In: Philippine Guidelines on Periodic Health Examination: Effective Screening for Diseases Among Apparently Healthy Filipinos (Manila) pp. 105-18.
12. Quaglio G, Lugoboni F, Talamini G, et al. (2002) Prevalence of tuberculosis infection and comparison of multiple-puncture liquid tuberculin test and Mantoux test among drug users. Scand J Infect Dis 34, 574-6.
13. Woo J, Chan HS, Hazlett CB, et al. (1996) Tuberculosis among elderly Chinese in residential homes: Tuberculin reactivity and estimated prevalence. Gerontology 42, 155-62.
14. Barnes PF, Verdegun TD, Vachon LA, et al. (1988) Chest roentgenogram in pulmonary tuberculosis: New data on an old test. Chest 94, 316-20.
15. Cohen R, Muzaffar S, Capellan J, et al. (1996) The validity of classic symptoms and chest radiographic configuration in predicting tuberculosis. Chest 109, 420-3.
16. El-Solh A, Mylotte J, Sherif S, et al. (1997) Validity of a decision tree for predicting active pulmonary tuberculosis. Am J Respir Crit Care Med 155, 1711-6.
17. Tattevin P, Casalino E, Fleury L, et al. (1999) The validity of medical history, classical symptoms, and chest radiographs in predicting pulmonary tuberculosis - derivation of a pulmonary tuberculosis prediction model. Chest 115, 1248-53.
18. Task Force on Tuberculosis, Philippine Practice Guidelines Group in Infectious Diseases. (2000) Pulmonary Tuberculosis: Clinical Practice Guidelines. PPGG-ID Philippine Society for Microbiology and Infectious Diseases and Philippine College of Chest Physicians, Quezon City, 1, 3, 22-80.
19. Boiselle PM, Tocino I, Hooley RJ, et al. (1997) Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients: Accuracy, distinguishing features, and mimics. J Thorac Imaging 12, 47-53.
20. Al Kubaisy W, Al Dulayme A, Hashim DS (2003) Active Tuberculosis among Iraqi Schoolchildren with Positive Skin Tests and Their Household Contacts. East Med Health J 9, 675-88.
21. Wang PD, Lin RS (2000) Tuberculosis Transmission in the Family. J Infect 4, 249-51.
22. Davidow AL, Mangura BT, Wolman MS, et al. (2003) Workplace contact investigations in the United States. Int J Tuberc Lung Dis 7, S446-52.
23. Golub JE, Cronin WA, Obasanjo OO, et al. (2001) Transmission of Mycobacterium tuberculosis through casual contact with an infectious case. Arch Intern Med 161, 2254-8.
24. Beser E (1993) The prevalence of pulmonary tuberculosis using different methods in Group screenings. East Afr Med J 70, 768-71.
25. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev (2), CD001363.
26. CDC. (2003) Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR 52, 735-9.
27. British Thoracic Society Standards of Care Committee. (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60, 800-5.
28. American Thoracic Society. (2000) Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med 161, S221-47.